Key Success Factors in Pricing, Reimbursement and Market Access Novel pricing and reimbursement models are shaping the uptake of medicines. Yet the market access goalposts keep being moved as payer policies, needs and...

This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and...

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY...

Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached...

This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics covered include expert opinions on; Seattle Genetics reporting the...

Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity but are the right steps being taken to address the most fundamental patient issue: non-adherence? Is ‘big...

Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...

This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib)...